Sacromeric proteins directed PROTACs as a personalized approach in Hypertrophic cardiomyopathy

Sacromeric proteins directed PROTACs as a personalized approach in Hypertrophic cardiomyopathy

Description of the granted funding

Our research aims to prevent the development of Hypertrophic Cardiomyopathy (HCM), a heart condition, in patients with mutations in the TRIM63 gene. Our project has three main goals: -Creating a Heart-on-a-Chip Model: We will develop a miniature, lab-grown heart model using patient-derived stem cells. This model will help us study the disease and test potential treatments in a controlled environment. -Designing Targeted Treatments: We plan to create specialized molecules called PROTACs that can remove the harmful proteins from heart cells. This innovative approach uses the body's natural system to eliminate disease-causing proteins. -Testing the Treatments: We will test these PROTACs in our heart-on-a-chip model to see if they can reduce or reverse the heart damage caused by the disease. This project involves collaboration between international laboratories, combining advanced techniques in computer modeling, chemistry, and tissue engineering.
Show more

Starting year

2025

End year

2028

Granted funding

Antti Poso Orcid -palvelun logo
199 799 €

Funder

Research Council of Finland

Funding instrument

International joint call

Other information

Funding decision number

367827

Fields of science

Pharmacy

Research fields

Farmasia
Sacromeric proteins directed PROTACs as a personalized approach in Hypertrophic cardiomyopathy - Research.fi